급성기 및 가속기 만성 골수성 백혈병에서 MCNU 단독요법 및 복합항암화학요법의 치료효과
Chemotherapy Including MCNU for the Treatment of Terminal Phase Chronic Myelogenous Leukemia
대한암학회지 1993년 25권 2호 p.247 ~ 251
소속 상세정보
김동욱
김희제/김희열/유기동/이종욱/진종률/한치화/민우성/박종원
KMID : 0360319930250020247
Abstract
A 66% response was obtained in 30 evaluable patients in the terminal phase CML(AP:: 19, BC: 11) using MCNU single or combination chemotherapy(MCNU, Etoposide, and Hydroxyurea). 26%(5/19 cases) of responses were complete in accelerated pahse and
9%(1/11
cases) in blastic crisis. A 47%(9/19 cases) partial response was obtained in accelerated phase and 45%(5/11 cases) in blastic phase.
Overall median survival of responder was 8 months(range: 4~11 months). Side effects were minimal and there were no treatment associated mortality and severe bone marrow failure. these results suggest that MCNU is a sate and valuable addition to
the
therapeutic repertoire for the control of terminal phase CML and patients getting a chance of secondary chronic phase might be indicated for allogenic allogenic bone marrow transplantation.
키워드
원문 및 링크아웃 정보
등재저널 정보